These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31955454)

  • 1. Hypophosphatemia in children treated with ferric carboxymaltose.
    Posod A; Schaefer B; Mueller T; Zoller H; Kiechl-Kohlendorfer U
    Acta Paediatr; 2020 Jul; 109(7):1491-1492. PubMed ID: 31955454
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM
    Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 10. What is wrong in doing good?
    Zoller H; Wagner S; Schaefer B
    Br J Haematol; 2023 Sep; 202(6):1089-1090. PubMed ID: 37528542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 12. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypophosphatemia associated with use of intravenous ferric carboxymaltose].
    Proaño Fierro ME; Rodríguez Cañete BL; Sánchez Sobrino P; Rego Iraeta AL
    Nutr Hosp; 2023 Dec; 40(6):1301-1304. PubMed ID: 37929853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric carboxymaltose (Injectafer) for iron deficiency anemia.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):99-100. PubMed ID: 24322665
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatal anaphylactic reaction due to ferric carboxymaltose: A case report.
    Arici AM; Kumral Z; Gelal A; Akdeniz B
    Anatol J Cardiol; 2020 Aug; 24(2):115-117. PubMed ID: 32749249
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain.
    Chauhan A; Lucas S; Garg M
    Gut; 2024 May; 73(6):1039. PubMed ID: 37193585
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Ferric Carboxymaltose Desensitization in a Patient With Prior Reactions to Intravenous Iron Therapies.
    Elmes JB; Moore DC; Pineda-Roman M
    Am J Ther; 2024 Mar-Apr 01; 31(2):e205-e206. PubMed ID: 37433089
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
    Mani LY; Nseir G; Venetz JP; Pascual M
    Transplantation; 2010 Oct; 90(7):804-5. PubMed ID: 20881582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.